Propranolol drug interactions

Revision as of 23:36, 4 February 2014 by ShiSheng (talk | contribs) (Changed protection level for "Propranolol drug interactions" ([Edit=Allow only autoconfirmed users] (expires 23:36, 11 February 2014 (UTC)) [Move=Allow only autoconfirmed users] (expires 23:36, 11 February 2014 (UTC))))
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Caution should be exercised when Propranolol hydrochloride extended-release is administered with drugs that have an affect on CYP2D6, 1A2, or 2C19 metabolic pathways. Co-administration of such drugs with Propranolol may lead to clinically relevant drug interactions and changes on its efficacy and/or toxicity.

List of drug & substance interactions


Alcohol

Cardiovascular Drugs

Antiarrhythmics

Digitalis Glycosides

Calcium Channel Blockers

ACE Inhibitors

Alpha Blockers

Inotropic Agents

Non-Cardiovascular Drugs

Nonsteroidal Anti-Inflammatory Drugs

Antidepressants

Anesthetic Agents

Neuroleptic Drugs

Complete list of drug interactions

Major interactions

Moderate interactions

Minor interactions



Alcohol

Alcohol when used concomitantly with Propranolol, may increase plasma levels of Propranolol.

Return to top

Cardiovascular Drugs

Antiarrhythmics

Propafenone has negative inotropic and beta-blocking properties that can be additive to those of Propranolol.

Quinidine increases the concentration of Propranolol and produces greater degrees of clinical beta-blockade and may cause postural hypotension.

Amiodarone is an antiarrhythmic agent with negative chronotropic properties that may be additive to those seen with β-blockers such as Propranolol.

The clearance of lidocaine is reduced with administration of Propranolol. Lidocaine toxicity has been reported following co-administration with Propranolol.

Caution should be exercised when administering Propranolol hydrochloride extended-release with drugs that slow A-V nodal conduction, e.g., lidocaine and calcium channel blockers.

Return to top

Digitalis Glycosides

Both digitalis glycosides and beta-blockers slow atrioventricular conduction and decrease heart rate. Concomitant use can increase the risk of bradycardia.

Return to top

Calcium Channel Blockers

Caution should be exercised when patients receiving a beta-blocker are administered a calcium channel-blocking drug with negative inotropic and/or chronotropic effects. Both agents may depress myocardial contractility or atrioventricular conduction.

There have been reports of significant bradycardia, heart failure, and cardiovascular collapse with concurrent use of verapamil and beta-blockers.

Co-administration of Propranolol and diltiazem in patients with cardiac disease has been associated with bradycardia, hypotension, high degree heart block, and heart failure.

Return to top

ACE Inhibitors

When combined with beta-blockers, ACE inhibitors can cause hypotension, particularly in the setting of acute myocardial infarction.

The antihypertensive effects of clonidine may be antagonized by beta-blockers. Propranolol hydrochloride extended-release should be administered cautiously to patients withdrawing from clonidine.

Return to top

Alpha Blockers

Prazosin has been associated with prolongation of first dose hypotension in the presence of beta-blockers.

Postural hypotension has been reported in patients taking both beta-blockers and terazosin or doxazosin.

Reserpine

Patients receiving catecholamine-depleting drugs, such as reserpine should be closely observed for excessive reduction of resting sympathetic nervous activity, which may result in hypotension, marked bradycardia, vertigo, syncopal attacks, or orthostatic hypotension.

Return to top

Inotropic Agents

Patients on long-term therapy with Propranolol may experience uncontrolled hypertension if administered epinephrine as a consequence of unopposed alpha-receptor stimulation. Epinephrine is therefore not indicated in the treatment of Propranolol overdose.

Isoproterenol and Dobutamine

Propranolol is a competitive inhibitor of beta-receptor agonists, and its effects can be reversed by administration of such agents, e.g., dobutamine or isoproterenol. Also, Propranolol may reduce sensitivity to dobutamine stress echocardiography in patients undergoing evaluation for myocardial ischemia.

Return to top

Non-Cardiovascular Drugs

Nonsteroidal Anti-Inflammatory Drugs

Nonsteroidal anti-inflammatory drugs (NSAIDs) have been reported to blunt the antihypertensive effect of beta-adrenoreceptor blocking agents.

Administration of indomethacin with Propranolol may reduce the efficacy of Propranolol in reducing blood pressure and heart rate.

Return to top

Antidepressants

The hypotensive effects of MAO inhibitors or tricyclic antidepressants may be exacerbated when administered with beta-blockers by interfering with the beta blocking activity of Propranolol.

Return to top

Anesthetic Agents

Methoxyflurane and trichloroethylene may depress myocardial contractility when administered with Propranolol.

Warfarin: Propranolol when administered with warfarin increases the concentration of warfarin. Prothrombin time, therefore, should be monitored.

Return to top

Neuroleptic Drugs

Hypotension and cardiac arrest have been reported with the concomitant use of Propranolol and haloperidol.

Thyroxine: Thyroxine may result in a lower than expected T3 concentration when used concomitantly with Propranolol.

Return to top

Complete list of drug interactions

Major Interactions

Return to top

Moderate Interactions

0-9

Return to top

A


Return to top

B


Return to top

C


Return to top

D


Return to top

E

Return to top

F

Return to top

G

Return to top

H

Return to top

I

Return to top

K

Return to top

L

Return to top

M

Return to top

N

Return to top

O

Return to top

P

Return to top

Q

Return to top

R

Return to top

S

Return to top

T

Return to top

U

Return to top

V

Return to top

W

Return to top

X

Return to top

Z

Return to top

Minor Interactions

A


Return to top

B


Return to top

C


Return to top

D


Return to top

E


Return to top

F


Return to top

G


Return to top

H


Return to top

I


Return to top

J


Return to top

K


Return to top

L


Return to top

M


Return to top

N


Return to top

O


Return to top

P

Return to top

Q

Return to top

R

Return to top

S

Return to top

T

Return to top

U

Return to top

V

Return to top

W

Return to top

Y

Return to top

Z

Return to top




Adapted from the FDA Package Insert.